目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 PRIMARY INSIGHTS
2.2.2 VACCINE MARKET : SEGMENT ASSESSMENT METHODOLOGY
2.3 MARKET GROWTH RATE ASSUMPTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 STUDY ASSUMPTIONS
2.8 RISK ANALYSIS
2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 VACCINE MARKET OVERVIEW
4.2 NORTH AMERICA: VACCINE MARKET , BY PRODUCT AND COUNTRY (2022)
4.3 VACCINE MARKET , BY PRODUCT, 2023 VS. 2028
4.4 VACCINE MARKET : GEOGRAPHIC GROWTH OPPORTUNITES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
5.3 MARKET DYNAMICS
5.3.1 DRIVERS
5.3.2 RESTRAINTS
5.3.3 OPPORTUNITIES
5.3.4 CHALLENGES
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 ECOSYSTEM ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 VALUE CHAIN ANALYSIS
5.8 REGULATORY LANDSCAPE
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES,AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE TREND BY KEY PLAYERS, BY TECHNOLOGY
5.9 INDICATIVE PRICING ANALYISIS
5.10 TECHNOLOGY ANALYSIS
5.11 PATENT ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT FROM NEW ENTRANTS
5.13.2 THREAT OF SUBSITITUTE
5.13.3 BARGAINING POWER OF SUPPLERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITION RIVARLY
5.14 PIPELLINE ANALYSIS & KEY PIPELINE PRODUCTS
5.15 NEW VACCINE OPPORTUNITIES
5.15.1 HIV
5.15.2 MALARIA
5.15.3 ZIKA
5.15.4 EBOLA
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.13.1 BUYING CRITERIA

6 VACCINE MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
6.2 CONJUGATE VACCINES
6.3 RECOMBINANT VACCINES
6.4 INACTIVATED AND SUBUNIT VACCINES
6.5 LIVE ATTENUATED VACCINES
6.6 TOXOID VACCINES
6.7 VIRAL VECTOR VACCINES
6.8 M-RNA VACCINES
6.9 OTHERS (SUBUNIT VACCINES, PEPTIDE VACCINES, DNA VACCINES)

7 VACCINE MARKET, BY TYPE
7.1 INTRODUCTION
7.2 MONOVALENT VACCINES
7.3 MULTIVALENT VACCINES

8 VACCINE MARKET, BY DISEASE INDICATION
8.1 INTRODUCTION
8.2 PNEUMOCOCCAL DISEASE
8.2 INFLUENZA
8.3 COMBINATION VACCINES
8.4 HPV
8.5 MENINGOCOCCAL DISEASE
8.6 HERPES ZOSTER
8.7 ROTAVIRUS
8.8 MMR
8.9 VARICELLA
8.10 HEPATITIS
8.11 DTP
8.12 POLIO
8.13 OTHER DISEASE INDICATIONS (CANCER, COVID-19, DENGUE, TUBERCULOSIS, TYPHOID, JAPANESE ENCEPHALITIS, RABIES, YELLOW FEVER, AND ALLERGIES)

9 VACCINE MARKET, BY ROUTE OF ADMINISTRATION
9.1 INTRODUCTION
9.2 INTRAMUSCULAR & SUBCUTANEOUS
9.3 ORAL
9.4 OTHERS (INTRANASAL, INTRADERMAL)

10 VACCINE MARKET, BY END USER
10.1 INTRODUCTION
10.2 PEDIATRIC VACCINE
10.3 ADULT VACCINE

11 VACCINE MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.2.3 RECESSION IMPACT
11.3 EUROPE
11.3.1 GERMANY
11.3.2 UK
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.3.7 RECESSION IMPACT
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.2 SOUTH KOREA
11.4.3 CHINA
11.4.4 INDIA
11.4.5 REST OF APAC
11.4.6 RECESSION IMPACT
11.5 LATIN AMERICA
11.5.1 BRAZIL
11.5.2 MEXICO
11.5.3 ROLATAM
11.5.4 RECESSION IMPACT
11.6 MIDDLE EAST
11.6.1 RECESSION IMPACT
11.7 AFRICA
11.7.1 RECESSION IMPACT

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
12.3 MARKET SHARE ANALYSIS
12.4 REVENUE SHARE ANALYSIS
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING
12.7 COMPETITIVE SCENARIO AND TRENDS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 GSK PLC
13.1.2 MERCK & CO., INC
13.1.3 PFIZER, INC
13.1.4 SANOFI
13.1.5 CSL
13.1.6 EMERGENT
13.1.7 JOHNSON & JOHNSON SERVICES, INC
13.1.8 ASTRAZENECA
13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD
13.1.10 BAVARIAN NORDIC
13.1.11 MITSUBISHI TANABE PHARMA CORPORATION (MITSUBISHI CHEMICAL GROUP COMPANY)
13.1.12 DAIICHI SANKYO COMPANY, LIMITED.
13.1.13 PANACEA BIOTEC
13.1.14 BIOLOGICAL E LIMITED
13.1.15 BHARAT BIOTECH
13.1.16 NOVAVAX
13.1.17 INOVIO PHARMACEUTICALS
13.2 OTHER COMPANIES
13.2.1 SINOVAC
13.2.2 INCEPTA PHARMA
13.2.3 VALNEVA SE
13.2.4 VBI VACCINES INC
13.2.5 BIO FARMA
13.2.6 FSUE NPO MICROGEN
13.2.7 ZHI FEI BIOLOGICAL
13.2.8 INDIAN IMMUNOLOGICALS LTD.

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS